Insomnia News and Research

Latest Insomnia News and Research

Health Canada accepts Paladin's Silenor NDS for review

Paladin Labs Inc. and Somaxon Pharmaceuticals, Inc. today announced that Paladin has filed a New Drug Submission (NDS) that has been accepted for review by Health Canada for Silenor (doxepin) for the treatment and symptomatic relief of insomnia.

23 Feb 2012

AstraZeneca launches ARIMIDEX Direct to help cancer patients

AstraZeneca today announced its first-ever direct-to-patient program offering patients with a valid prescription for ARIMIDEX or anastrozole the opportunity to have the brand ARIMIDEX delivered directly to their home by Express Scripts, a specialty pharmacy services provider, for $40 per month, including shipping.

17 Feb 2012

Acorda's fourth quarter GAAP net income increases to $12.7 million

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2011.

16 Feb 2012

Valeant receives FDA approval for secondary supplier of Methoxsalen

The FDA has approved the addition of a secondary supplier of Methoxsalen USP, an integral component of a treatment for the relief of moderate to severe psoriasis prescribed under the brand name Oxsoralen-Ultra (methoxsalen) Capsules, USP, 10mg.

15 Feb 2012

What is the optimum amount of sleep for kids?

New research shows that children are getting less sleep than they need. According to an article published online Monday by the journal Pediatrics, 32 sets of sleep guidelines for kids – containing 360 distinct recommendations for children of specific ages – were published between 1897 and 2009. During that time, the amount of recommended sleep fell by an average of 0.71 minutes per year. That added up to about 70 fewer minutes of suggested nightly sleep over the course of the 20th century.

14 Feb 2012

Now on stands - Inhaled caffeine

A Harvard professor has come up with a device that helps people inhale their caffeine from a lipstick-sized tube. Critics say the novel product, called “AeroShot,” is not without its risks. The product went on the market late last month in Massachusetts and New York, and is also available in France. A single unit costs $2.99 at convenience, mom-and-pop, liquor and online stores.

9 Feb 2012

Merck applies for approval of its new insomnia drug suvorexant

Merck & Co. announced this Monday that they would file for U.S. marketing approval of their experimental insomnia drug suvorexant in 2012.

7 Feb 2012

Merck completes two suvorexant Phase III trials on insomnia

Merck, known as MSD outside the United States and Canada, today provided an update on the development program for suvorexant, the company's investigational orexin receptor antagonist, which, if approved, will be a new mechanism for the treatment of insomnia.

7 Feb 2012

Takeda launches EDARBYCLOR in the U.S. for treatment of hypertension

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., announced EDARBYCLOR (azilsartan medoxomil and chlorthalidone) is now available by prescription in U.S. pharmacies for the treatment of hypertension to lower blood pressure in adults.

6 Feb 2012

Sleep disorders cost the economy billions

New figures reveal that sleep disorders are costing the Australian economy more than $5.1 billion each year. The staggering amount covers health costs and loss of productivity for the more than 1.5 million workers suffering from sleep disorders including sleep apnea and insomnia.

3 Feb 2012

Takeda, SPI announce that lubiprostone phase 3 trial on OBD meets primary endpoint

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.

2 Feb 2012

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE(bortezomib), which updates the label to include the subcutaneous method of administration in all approved indications: multiple myeloma and mantle cell lymphoma after at least one prior therapy.

24 Jan 2012

Now cannabis mouth spray to help ‘pot’ addicts quit

To help smokers quit there are nicotine patches and heroin users have methadone. However till date cannabis users have little choice except stop abruptly to quit. Cannabis withdrawal symptoms include severe insomnia, pot cravings and mood swings. “Although these are not life-threatening, they are significant enough to cause marked distress and lead people to go back to using the drug,” said lead researcher Jan Copeland.

10 Jan 2012

FDA approval of raltegravir offers new weapon to treat HIV infection in children

For children and adolescents with HIV infection, the recent Food and Drug Administration (FDA) approval of the use of raltegravir, an antiretroviral drug that slows the spread of HIV infection, offers a new weapon to treat HIV infection in children.

7 Jan 2012

Lundbeck announces availability of ONFI Tablets in the U.S.

Lundbeck announced today that ONFI Tablets are now available for prescribing in the United States. The FDA recently approved ONFI for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients two years and older.

4 Jan 2012

Lundbeck invests in Ossianix to focus on biotherapeutics for CNS disorders

Ossianix, Inc. today announced a strategic investment by H. Lundbeck A/S in the form of a Convertible Promissory Note. The proceeds from Lundbeck's investment is expected to allow Ossianix to generate biopharmaceuticals for the treatment of nervous system disorders by utilizing Ossianix's proprietary single domain antibody platform modeled on the shark vNAR structure.

3 Jan 2012

Oak Pharmaceuticals acquires three Lundbeck hospital-based injectables

Akorn, Inc., a niche generic pharmaceutical company, today announced that its wholly-owned subsidiary, Oak Pharmaceuticals, has acquired three off-patent, branded, hospital-based injectables from the US subsidiary of H. Lundbeck A/S.

23 Dec 2011

FDA approves Merck's Isentress to treat HIV-1 infection in children, adolescents

Isentress (raltegravir) was approved today by the U.S. Food and Drug Administration for use with other antiretroviral drugs for the treatment of HIV-1 infection for children and adolescents ages 2-18.

22 Dec 2011

ACTF, Merck announce new HIV initiatives

Today, Merck, known as MSD outside the United States and Canada, and the ADAP Crisis Task Force (ACTF) announced a number of new initiatives to help struggling state AIDS Drug Assistance Programs (ADAPs) continue to provide access to medicines to people living with HIV.

22 Dec 2011

Survey: 40% of police officers have sleep disorders

A survey of police officers indicated that about 40 percent have a sleep disorder, which was associated with an increased risk of adverse health, safety and performance outcomes, according to a study in the December 21 issue of JAMA.

21 Dec 2011